Meeting
2019 Breakthrough
Clinical study of gefitinib maintenance therapy after concurrent radiotherapy and chemotherapy for locally advanced NSCLC with EGFR sensitive mutations.
Authors
Ying Xin
Jilin Cancer Hospital (JCH), Changchun, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Therapeutic Interventions and Treatment
Track
Therapeutic Interventions,Treatment
Sub Track
Therapeutic Interventions
Citation
J Glob Oncol 5, 2019 (suppl 1; abstr 87)
DOI
10.1200/JGO.2019.5.suppl.87
Abstract #
87
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
First Author: Alexandra Pender
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson